AUPH
Price
$8.14
Change
-$0.10 (-1.21%)
Updated
Jan 29 closing price
Capitalization
1.17B
33 days until earnings call
DYAI
Price
$1.47
Change
-$0.06 (-3.92%)
Updated
Jan 29 closing price
Capitalization
43.5M
55 days until earnings call
Ad is loading...

AUPH vs DYAI

Header iconAUPH vs DYAI Comparison
Open Charts AUPH vs DYAIBanner chart's image
Aurinia Pharmaceuticals
Price$8.14
Change-$0.10 (-1.21%)
Volume$860K
Capitalization1.17B
Dyadic International
Price$1.47
Change-$0.06 (-3.92%)
Volume$23.25K
Capitalization43.5M
AUPH vs DYAI Comparison Chart
Loading...
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DYAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AUPH vs. DYAI commentary
Jan 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUPH is a Buy and DYAI is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Jan 30, 2025
Stock price -- (AUPH: $8.14 vs. DYAI: $1.47)
Brand notoriety: AUPH and DYAI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUPH: 62% vs. DYAI: 19%
Market capitalization -- AUPH: $1.17B vs. DYAI: $43.5M
AUPH [@Biotechnology] is valued at $1.17B. DYAI’s [@Biotechnology] market capitalization is $43.5M. The market cap for tickers in the [@Biotechnology] industry ranges from $379.55B to $0. The average market capitalization across the [@Biotechnology] industry is $2.47B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUPH’s FA Score shows that 0 FA rating(s) are green whileDYAI’s FA Score has 0 green FA rating(s).

  • AUPH’s FA Score: 0 green, 5 red.
  • DYAI’s FA Score: 0 green, 5 red.
According to our system of comparison, AUPH is a better buy in the long-term than DYAI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUPH’s TA Score shows that 4 TA indicator(s) are bullish while DYAI’s TA Score has 3 bullish TA indicator(s).

  • AUPH’s TA Score: 4 bullish, 5 bearish.
  • DYAI’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, AUPH is a better buy in the short-term than DYAI.

Price Growth

AUPH (@Biotechnology) experienced а +5.30% price change this week, while DYAI (@Biotechnology) price change was -5.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.08%. For the same industry, the average monthly price growth was +1.14%, and the average quarterly price growth was +3.33%.

Reported Earning Dates

AUPH is expected to report earnings on May 01, 2025.

DYAI is expected to report earnings on Mar 26, 2025.

Industries' Descriptions

@Biotechnology (+0.08% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AUPH($1.17B) has a higher market cap than DYAI($43.5M). AUPH YTD gains are higher at: -9.354 vs. DYAI (-16.000). AUPH has higher annual earnings (EBITDA): 4.39M vs. DYAI (-7.42M). AUPH has more cash in the bank: 349M vs. DYAI (9.92M). DYAI has less debt than AUPH: DYAI (5.37M) vs AUPH (87.9M). AUPH has higher revenues than DYAI: AUPH (220M) vs DYAI (3.37M).
AUPHDYAIAUPH / DYAI
Capitalization1.17B43.5M2,678%
EBITDA4.39M-7.42M-59%
Gain YTD-9.354-16.00058%
P/E RatioN/AN/A-
Revenue220M3.37M6,538%
Total Cash349M9.92M3,517%
Total Debt87.9M5.37M1,637%
FUNDAMENTALS RATINGS
AUPH vs DYAI: Fundamental Ratings
AUPH
DYAI
OUTLOOK RATING
1..100
262
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
94
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9198
PRICE GROWTH RATING
1..100
4749
P/E GROWTH RATING
1..100
10074
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AUPH's Valuation (41) in the Biotechnology industry is somewhat better than the same rating for DYAI (94). This means that AUPH’s stock grew somewhat faster than DYAI’s over the last 12 months.

AUPH's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DYAI (100). This means that AUPH’s stock grew similarly to DYAI’s over the last 12 months.

AUPH's SMR Rating (91) in the Biotechnology industry is in the same range as DYAI (98). This means that AUPH’s stock grew similarly to DYAI’s over the last 12 months.

AUPH's Price Growth Rating (47) in the Biotechnology industry is in the same range as DYAI (49). This means that AUPH’s stock grew similarly to DYAI’s over the last 12 months.

DYAI's P/E Growth Rating (74) in the Biotechnology industry is in the same range as AUPH (100). This means that DYAI’s stock grew similarly to AUPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AUPHDYAI
RSI
ODDS (%)
Bullish Trend 1 day ago
87%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
88%
Momentum
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
N/A
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 6 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
85%
View a ticker or compare two or three
Ad is loading...
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DYAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RIGGX37.22N/A
N/A
American Funds Intl Gr and Inc R6
LMNSX72.25-0.04
-0.06%
ClearBridge Small Cap I
VSPRX16.70-0.05
-0.30%
Voya Small Company Port R6
SDGAX123.23-0.97
-0.78%
DWS Capital Growth A
VICEX20.87-0.22
-1.04%
USA Mutuals Vice Investor

AUPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, AUPH has been loosely correlated with JSPR. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if AUPH jumps, then JSPR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUPH
1D Price
Change %
AUPH100%
-1.21%
JSPR - AUPH
44%
Loosely correlated
N/A
VCYT - AUPH
39%
Loosely correlated
+1.76%
GOSS - AUPH
37%
Loosely correlated
-0.24%
ADMA - AUPH
32%
Poorly correlated
+1.30%
SCPH - AUPH
31%
Poorly correlated
+0.61%
More

DYAI and

Correlation & Price change

A.I.dvisor tells us that DYAI and MDGL have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DYAI and MDGL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYAI
1D Price
Change %
DYAI100%
-3.92%
MDGL - DYAI
29%
Poorly correlated
-0.31%
FATE - DYAI
28%
Poorly correlated
+0.77%
SNPX - DYAI
27%
Poorly correlated
+1.20%
CGTX - DYAI
26%
Poorly correlated
+0.25%
AUPH - DYAI
24%
Poorly correlated
-1.21%
More